NCT03364400进行中（未招募）1 期
A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 116
- 试验地点
- 12
- 主要终点
- Identify recommended phase 2 dose by measuring incidence of dose limiting toxicities at increasing dose levels. Determine the safety and tolerability of VT1021 in ovarian, pancreatic, triple negative breast cancer, glioblastoma and CD36 high cohort.
研究概览
简要总结
This study is an an open-label Phase I trial of VT1021 in patients with advanced solid tumors. Patients must have recurrent or advanced cancer (i.e., solid tumors) for which standard therapy offers no curative potential.
详细描述
This is an open-label Phase I study of VT1021 in patients with advanced solid tumors. The study will include a Dose Escalation Phase and a Dose Expansion Phase. Upon determination of the Recommended Phase 2 Dose in the Dose Escalation Phase, the Dose Expansion Phase will be opened. The Dose Expansion Phase will include cohorts in ovarian, pancreatic, triple negative breast cancer, glioblastoma and CD36-high patients in order to confirm the tolerability of VT1021 against specific tumor types.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Dose Escalation Phase:
- •Patients must be refractory to, or intolerant of, existing therapies known to provide clinical benefit for their condition (i.e., cancer diagnosis)
- •Dose Expansion Phase:
- •Patients with confirmed diagnosis of unresectable epithelial ovarian, fallopian tube, or primary peritoneal cancer must have received ≤ 3 prior lines of therapy in a platinum resistant setting. BRCA mutant patients are excluded unless they have failed previous line with a PARP inhibitor
- •Pancreatic:
- •Patients with confirmed diagnosis of pancreatic cancer must have received ≤2 prior lines of therapy
- •Triple Negative Breast Cancer:
- •Patients with confirmed diagnosis of metastatic TNBC must have received ≤ 3 prior lines of therapy for metastatic disease
- •Glioblastoma:
- •Patients with confirmed relapsed or refractory glioblastoma must have received ≤2 prior lines of systemic therapy
- •CD36-high basket cohort:
- •Patients with solid tumor cancers that have high expression of CD36 by immunohistochemistry. Patients must have received ≤ 3 prior lines of therapy for metastatic disease
- •Patient has evaluable disease by RECIST v1.1
- •Patient has a performance status (PS) of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale
- •Patient is at least 21 days (12 weeks for glioblastoma patients) removed from therapeutic radiation or chemotherapy prior to the first scheduled day of dosing with VT1021
- •Patient has adequate organ function
- •Patient agrees to use acceptable methods of contraception during the study and 60 days after the last dose of VT1021
排除标准
- •Diagnosis of another malignancy within the past 2 years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, superficial bladder cancer, or endometrial cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment)
- •History of a major surgical procedure or a significant traumatic injury within 14 days prior to commencing treatment, or the anticipation of the need for a major surgical procedure during the course of the study
- •Treatment with investigational therapy(ies) within 5 half-lives of the investigational therapy prior to the first scheduled day of dosing with VT1021, or 4 weeks if the half-life of the investigational agent is not known
- •Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, New York Heart Association (NYHA) class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B, hepatitis C or HIV, or other significant co-morbid conditions that, in the opinion of the Investigator, would impair study participation or cooperation
- •Pregnancy or lactation
- •Evidence of symptomatic brain metastases. Patients with treated (surgically excised or irradiated) and stable brain metastases are eligible, assuming the patient has adequately recovered from treatment
- •Other concurrent chemotherapy, immunotherapy, radiotherapy or investigational therapy
- •Requirement to palliative radiotherapy to lesions that are defined as target lesions by RECIST criteria at the time of study entry
研究组 & 干预措施
VT1021
Experimental
Escalating doses of VT1021 to determine RP2D
干预措施: VT1021 (Drug)
结局指标
主要结局
Identify recommended phase 2 dose by measuring incidence of dose limiting toxicities at increasing dose levels. Determine the safety and tolerability of VT1021 in ovarian, pancreatic, triple negative breast cancer, glioblastoma and CD36 high cohort.
时间窗: 2 doses weekly for 4 week cycle
Increasing dose levels until RP2D determined.
次要结局
- To determine overall response rate by iRECIST(Through study completion, an average of 1 year)
- To characterize the adverse event profile of VT1021 monotherapy as measured by CTCAE v 5.0 in subjects with advanced solid tumors.(2 doses weekly for 4 week cycle)
- To analyze the serum/plasma levels collected from patients for concentrations of VT1021 using non-compartmental analysis to estimate the pharmacokinetic parameters of the terminal elimination of half-life(2 cycles of 2 doses weekly for 4 week cycle)
- To analyze the serum/plasma levels collected from patients for concentrations of VT1021 using non-compartmental analysis to estimate the pharmacokinetic parameter of Cmax(2 cycles of 2 doses weekly for 4 week cycle)
- To analyze the serum/plasma levels collected from patients for concentrations of VT1021 using non-compartmental analysis to estimate the pharmacokinetic parameter of Tmax(2 cycles of 2 doses weekly for 4 week cycle)
- To analyze the serum/plasma levels collected from patients for concentrations of VT1021 using non-compartmental analysis to estimate the pharmacokinetic parameters of clearance, volume of distribution at steady state (Vdss)(2 cycles of 2 doses weekly for 4 week cycle)
- To analyze the serum/plasma levels collected from patients for concentrations of VT1021 using non-compartmental analysis to estimate the pharmacokinetic parameter of AUC0-t(2 cycles of 2 doses weekly for 4 week cycle)
- To analyze the serum/plasma levels collected from patients for concentrations of VT1021 using non-compartmental analysis to estimate the pharmacokinetic parameter of AUC0-∞(2 cycles of 2 doses weekly for 4 week cycle)
- To determine preliminary evidence of efficacy of VT1021 monotherapy(Through study completion, an average of 1 year)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
1 期
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With CancerAcute Myeloid Leukemia (AML)Non-Hodgkins LymphomaBreast CancerCancerProstate CancerMultiple MyelomaNon-Small Cell Lung CancerSmall Cell Lung CancerNCT02391480AbbVie128
已完成
1 期
IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ AdenocarcinomaGastric CancerNCT05327231InxMed (Shanghai) Co., Ltd.33
Unknown
1 期
HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid TumorsSolid TumorNCT05360368Shanghai Henlius Biotech24
进行中（未招募）
1 期
A Study to Assess PV-10 Chemoablation of Cancer of the LiverCancer Metastatic to the LiverMetastatic MelanomaMetastatic Ocular MelanomaMetastatic Uveal MelanomaMetastatic Lung CancerMetastatic Colorectal CancerMetastatic Pancreatic CancerHepatocellular CarcinomaMetastatic Breast CancerMetastatic Colon CancerNCT00986661Provectus Biopharmaceuticals, Inc.78
招募中
1 期
A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04947033I-Mab Biopharma US Limited25